{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:02Z","timestamp":1794018542456,"version":"4.8.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear. Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM. However, its efficacy in treating CNS-MM has not been reported. We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1276295","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T03:16:26Z","timestamp":1697166986000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case"],"prefix":"10.3389","volume":"14","author":[{"given":"Yasa Gul","family":"Mutlu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sureyya","family":"Y\u0131g\u0131t Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senem","family":"Maral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Melek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafer","family":"Baslar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leylagul","family":"Kaynar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omur Gokmen","family":"Sevindik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194909","article-title":"The role of monoclonal antibodies in the era of bi-specifics antibodies and CAR T cell therapy in multiple myeloma","volume":"13","author":"Mohan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162440","article-title":"Arnulf B efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma na\u00efve to B-Cell Maturation Antigen (BCMA)-directed therapies: results from cohort a of the magnetismm-3 study","volume":"140","author":"Bahlis NJ","year":"2022","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blade","year":"2011","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001459","article-title":"Genetic basis of extramedullary plasmablastic transformation of multiple myeloma","volume":"44","author":"Liu","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24351","article-title":"Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice","volume":"91","author":"Jurczyszyn","year":"2016","journal-title":"Am J Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12414","article-title":"Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents","volume":"162","author":"Chen","year":"2013","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2174\/1871524914999140818111514","article-title":"Novel agents in CNS myeloma treatment","volume":"14","author":"Gozzetti","year":"2014","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26447","article-title":"Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients","volume":"118","author":"Gozzetti","year":"2012","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12351","article-title":"Cerebrospinal fluid penetrance of lenalidomide in meningeal myeloma","volume":"162","author":"Anwer","year":"2013","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071754","article-title":"Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models","volume":"8","author":"Li","year":"2013","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.07.229","article-title":"The daratumumab crosses the blood brain barrier","volume":"18","author":"Vercruyssen","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.5646-20","article-title":"Multiple myeloma with central nervous system relapse early after autologous stem cell transplantation: A case report and literature review","volume":"60","author":"Hotta","year":"2021","journal-title":"Intern Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/CJI.0000000000000391","article-title":"BCMA CAR-T therapy is safe and effective for refractory\/relapsed multiple myeloma with central nervous system involvement","volume":"45","author":"Wang","year":"2022","journal-title":"J Immunother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1276295\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T03:16:29Z","timestamp":1697166989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1276295\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":14,"alternative-id":["10.3389\/fimmu.2023.1276295"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1276295","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"article-number":"1276295"}}